189 related articles for article (PubMed ID: 10387090)
1. Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation.
Gueguen G; Gaigé B; Grévy JM; Rogalle P; Bellan J; Wilson M; Klaébé A; Pont F; Simon MF; Chap H
Biochemistry; 1999 Jun; 38(26):8440-50. PubMed ID: 10387090
[TBL] [Abstract][Full Text] [Related]
2. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.
Tokumura A; Sinomiya J; Kishimoto S; Tanaka T; Kogure K; Sugiura T; Satouchi K; Waku K; Fukuzawa K
Biochem J; 2002 Aug; 365(Pt 3):617-28. PubMed ID: 11982483
[TBL] [Abstract][Full Text] [Related]
3. N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors.
Liliom K; Bittman R; Swords B; Tigyi G
Mol Pharmacol; 1996 Sep; 50(3):616-23. PubMed ID: 8794902
[TBL] [Abstract][Full Text] [Related]
4. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.
Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W
Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of migration-resistant hydroxyethoxy analogues of lysophosphatidic acid.
Qian L; Xu Y; Arai H; Aoki J; McIntyre TM; Prestwich GD
Org Lett; 2003 Nov; 5(24):4685-8. PubMed ID: 14627415
[TBL] [Abstract][Full Text] [Related]
6. Structure--activity relationships of lysophosphatidic acid: conformationally restricted backbone mimetics.
Hopper DW; Ragan SP; Hooks SB; Lynch KR; Macdonald TL
J Med Chem; 1999 Mar; 42(6):963-70. PubMed ID: 10090779
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of monofluorinated analogues of lysophosphatidic acid.
Xu Y; Qian L; Prestwich GD
J Org Chem; 2003 Jun; 68(13):5320-30. PubMed ID: 12816494
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid-induced Ca2+ mobilization in human A431 cells: structure-activity analysis.
Jalink K; Hengeveld T; Mulder S; Postma FR; Simon MF; Chap H; van der Marel GA; van Boom JH; van Blitterswijk WJ; Moolenaar WH
Biochem J; 1995 Apr; 307 ( Pt 2)(Pt 2):609-16. PubMed ID: 7733903
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid is the unique platelet-activating substance in human malignant ascites.
Sandmann G; Siess W; Essler M
Eur J Med Res; 2003 Sep; 8(9):397-404. PubMed ID: 14555295
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction.
Rizza C; Leitinger N; Yue J; Fischer DJ; Wang DA; Shih PT; Lee H; Tigyi G; Berliner JA
Lab Invest; 1999 Oct; 79(10):1227-35. PubMed ID: 10532586
[TBL] [Abstract][Full Text] [Related]
11. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists.
Kranenburg O; Moolenaar WH
Oncogene; 2001 Mar; 20(13):1540-6. PubMed ID: 11313900
[TBL] [Abstract][Full Text] [Related]
12. Biochemical regulation of breast cancer cell expression of S1P2 (Edg-5) and S1P3 (Edg-3) G protein-coupled receptors for sphingosine 1-phosphate.
Dolezalova H; Shankar G; Huang MC; Bikle DD; Goetzl EJ
J Cell Biochem; 2003 Mar; 88(4):732-43. PubMed ID: 12577307
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a lysophosphatidic acid receptor.
Thomson FJ; Perkins L; Ahern D; Clark M
Mol Pharmacol; 1994 Apr; 45(4):718-23. PubMed ID: 8183251
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization.
Jin Y; Knudsen E; Wang L; Maghazachi AA
Eur J Immunol; 2003 Aug; 33(8):2083-9. PubMed ID: 12884281
[TBL] [Abstract][Full Text] [Related]
15. A lysophosphatidic acid analogue is revealed as a potent inhibitor of phosphatidylcholine synthesis, inducing apoptosis.
Gueguen G; Granci V; Rogalle P; Briand-Mésange F; Wilson M; Klaébé A; Tercé F; Chap H; Salles JP; Simon MF; Gaits F
Biochem J; 2002 Dec; 368(Pt 2):447-59. PubMed ID: 12197836
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.
Khandoga AL; Fujiwara Y; Goyal P; Pandey D; Tsukahara R; Bolen A; Guo H; Wilke N; Liu J; Valentine WJ; Durgam GG; Miller DD; Jiang G; Prestwich GD; Tigyi G; Siess W
Platelets; 2008 Sep; 19(6):415-27. PubMed ID: 18925509
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a receptor subtype-selective lysophosphatidic acid mimetic.
Hooks SB; Ragan SP; Hopper DW; Hönemann CW; Durieux ME; Macdonald TL; Lynch KR
Mol Pharmacol; 1998 Feb; 53(2):188-94. PubMed ID: 9463475
[TBL] [Abstract][Full Text] [Related]
18. Propofol inhibits human platelet aggregation induced by proinflammatory lipid mediators.
Fourcade O; Simon MF; Litt L; Samii K; Chap H
Anesth Analg; 2004 Aug; 99(2):393-8, table of contents. PubMed ID: 15271713
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of fluorinated lysophosphatidic acid analogues.
Xu Y; Aoki J; Shimizu K; Umezu-Goto M; Hama K; Takanezawa Y; Yu S; Mills GB; Arai H; Qian L; Prestwich GD
J Med Chem; 2005 May; 48(9):3319-27. PubMed ID: 15857137
[TBL] [Abstract][Full Text] [Related]
20. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
